A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility

Roos J. Jutten; John Harrison; Philippe R. Lee Meeuw Kjoe; Esther M. Opmeer; Niki S.M. Schoonenboom; Frank Jan de Jong; Craig W. Ritchie; Philip Scheltens; Sietske A.M. Sikkes

doi:10.1016/j.dadm.2017.12.002

A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility

Roos J. Jutten, John Harrison, Philippe R. Lee Meeuw Kjoe, Esther M. Opmeer, Niki S.M. Schoonenboom, Frank Jan de Jong, Craig W. Ritchie, Philip Scheltens, Sietske A.M. Sikkes

Centre for Affective Disorders

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

202 Downloads (Pure)

Abstract

Introduction To improve the detection of changes in Alzheimer's disease, we designed the cognitive-functional composite (CFC). As a first validation step, we investigated its test–retest reliability and feasibility of use. Methods We performed a test–retest study with 2–3 weeks between assessments, including patients with mild cognitive impairment or mild Alzheimer's disease dementia and cognitively healthy participants. We calculated intraclass correlation coefficients type absolute agreement for all CFC measures and compared baseline and retest scores using paired sample t-tests. We evaluated feasibility by interviewing participants. Results Forty-three patients (40% female, mean age = 69.9) and 30 controls (50% female, mean age = 65) were included. Subtest intraclass correlation coefficients ranged from .70 to .96. We found negligible improvements after retesting on only two subtests. Overall, patients perceived the administration of the CFC as feasible. Conclusions The CFC is a stable and feasible measure in mild cognitive impairment and mild Alzheimer's disease, and thereby meets important quality metrics for clinically meaningful outcome measures.

Original language	English
Pages (from-to)	153-160
Journal	Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume	10
DOIs	https://doi.org/10.1016/j.dadm.2017.12.002
Publication status	E-pub ahead of print - 27 Dec 2017

Keywords

Activities of daily living
Alzheimer's disease
Cognition
Feasibility
Test–retest reliability
Outcome measures

Access to Document

10.1016/j.dadm.2017.12.002Licence: CC BY-NC-ND

A novel cognitive-functional_JUTTEN_Publishedonline27December2017_GOLD VoR (CC BY)Final published version, 372 KBLicence: CC BY-NC-ND

Cite this

Jutten, R. J., Harrison, J., Lee Meeuw Kjoe, P. R., Opmeer, E. M., Schoonenboom, N. S. M., de Jong, F. J., Ritchie, C. W., Scheltens, P., & Sikkes, S. A. M. (2017). A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 10, 153-160. Advance online publication. https://doi.org/10.1016/j.dadm.2017.12.002

@article{7956b462daeb4233b412fcb01427019d,

title = "A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility",

abstract = "Introduction To improve the detection of changes in Alzheimer's disease, we designed the cognitive-functional composite (CFC). As a first validation step, we investigated its test–retest reliability and feasibility of use. Methods We performed a test–retest study with 2–3 weeks between assessments, including patients with mild cognitive impairment or mild Alzheimer's disease dementia and cognitively healthy participants. We calculated intraclass correlation coefficients type absolute agreement for all CFC measures and compared baseline and retest scores using paired sample t-tests. We evaluated feasibility by interviewing participants. Results Forty-three patients (40% female, mean age = 69.9) and 30 controls (50% female, mean age = 65) were included. Subtest intraclass correlation coefficients ranged from .70 to .96. We found negligible improvements after retesting on only two subtests. Overall, patients perceived the administration of the CFC as feasible. Conclusions The CFC is a stable and feasible measure in mild cognitive impairment and mild Alzheimer's disease, and thereby meets important quality metrics for clinically meaningful outcome measures.",

keywords = "Activities of daily living, Alzheimer's disease, Cognition, Feasibility, Test–retest reliability, Outcome measures",

author = "Jutten, {Roos J.} and John Harrison and {Lee Meeuw Kjoe}, {Philippe R.} and Opmeer, {Esther M.} and Schoonenboom, {Niki S.M.} and {de Jong}, {Frank Jan} and Ritchie, {Craig W.} and Philip Scheltens and Sikkes, {Sietske A.M.}",

year = "2017",

month = dec,

day = "27",

doi = "10.1016/j.dadm.2017.12.002",

language = "English",

volume = "10",

pages = "153--160",

journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",

issn = "2352-8729",

publisher = "Elsevier BV",

}

Jutten, RJ, Harrison, J, Lee Meeuw Kjoe, PR, Opmeer, EM, Schoonenboom, NSM, de Jong, FJ, Ritchie, CW, Scheltens, P & Sikkes, SAM 2017, 'A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility', Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, vol. 10, pp. 153-160. https://doi.org/10.1016/j.dadm.2017.12.002

A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility. / Jutten, Roos J.; Harrison, John; Lee Meeuw Kjoe, Philippe R. et al.
In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 10, 27.12.2017, p. 153-160.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease

T2 - Test–retest reliability and feasibility

AU - Jutten, Roos J.

AU - Harrison, John

AU - Lee Meeuw Kjoe, Philippe R.

AU - Opmeer, Esther M.

AU - Schoonenboom, Niki S.M.

AU - de Jong, Frank Jan

AU - Ritchie, Craig W.

AU - Scheltens, Philip

AU - Sikkes, Sietske A.M.

PY - 2017/12/27

Y1 - 2017/12/27

N2 - Introduction To improve the detection of changes in Alzheimer's disease, we designed the cognitive-functional composite (CFC). As a first validation step, we investigated its test–retest reliability and feasibility of use. Methods We performed a test–retest study with 2–3 weeks between assessments, including patients with mild cognitive impairment or mild Alzheimer's disease dementia and cognitively healthy participants. We calculated intraclass correlation coefficients type absolute agreement for all CFC measures and compared baseline and retest scores using paired sample t-tests. We evaluated feasibility by interviewing participants. Results Forty-three patients (40% female, mean age = 69.9) and 30 controls (50% female, mean age = 65) were included. Subtest intraclass correlation coefficients ranged from .70 to .96. We found negligible improvements after retesting on only two subtests. Overall, patients perceived the administration of the CFC as feasible. Conclusions The CFC is a stable and feasible measure in mild cognitive impairment and mild Alzheimer's disease, and thereby meets important quality metrics for clinically meaningful outcome measures.

AB - Introduction To improve the detection of changes in Alzheimer's disease, we designed the cognitive-functional composite (CFC). As a first validation step, we investigated its test–retest reliability and feasibility of use. Methods We performed a test–retest study with 2–3 weeks between assessments, including patients with mild cognitive impairment or mild Alzheimer's disease dementia and cognitively healthy participants. We calculated intraclass correlation coefficients type absolute agreement for all CFC measures and compared baseline and retest scores using paired sample t-tests. We evaluated feasibility by interviewing participants. Results Forty-three patients (40% female, mean age = 69.9) and 30 controls (50% female, mean age = 65) were included. Subtest intraclass correlation coefficients ranged from .70 to .96. We found negligible improvements after retesting on only two subtests. Overall, patients perceived the administration of the CFC as feasible. Conclusions The CFC is a stable and feasible measure in mild cognitive impairment and mild Alzheimer's disease, and thereby meets important quality metrics for clinically meaningful outcome measures.

KW - Activities of daily living

KW - Alzheimer's disease

KW - Cognition

KW - Feasibility

KW - Test–retest reliability

KW - Outcome measures

U2 - 10.1016/j.dadm.2017.12.002

DO - 10.1016/j.dadm.2017.12.002

M3 - Article

SN - 2352-8729

VL - 10

SP - 153

EP - 160

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

ER -

Jutten RJ, Harrison J, Lee Meeuw Kjoe PR, Opmeer EM, Schoonenboom NSM, de Jong FJ et al. A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 2017 Dec 27;10:153-160. Epub 2017 Dec 27. doi: 10.1016/j.dadm.2017.12.002

A novel cognitive-functional composite measure to detect changes in early Alzheimer's disease: Test–retest reliability and feasibility

Abstract

Keywords

Access to Document

Fingerprint

Cite this